Abstract:A 41-year-old man with oral pemphigus vulgaris (PV) presented to our clinic with a history of no response to numerous immunosuppressant agents and was referred for extracorporeal photopheresis (ECP) therapy. Although the patient underwent a high-intensity ECP regimen for 5 months, which included two different photopheresis systems, his oral dysesthesia continued to interfere with oral intake, leading to continued weight loss and other adverse events. The intervention was associated with changes in several immu… Show more
“…The majority of the ECP studies and case reports on pemphigus disease treatment pertains to PV ( n = 14) [ 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 ]. A recent retrospective study on the efficacy of ECP was conducted on eight patients who were diagnosed with drug-resistant PV and who were refractory to first-line treatments, such as corticosteroids and adjuvant therapies, such as colchine [ 104 ].…”
Section: Psoriasismentioning
confidence: 99%
“…Although the majority of the studies validate the hypothesis that ECP is beneficial for the treatment of bullous diseases, one recent case report states that high-intensity ECP failed to treat a patient with refractory PV after 5 months of treatment. Immunophenotyping showed no change in the auto-antibody desmoglein titers, and the patient continued to experience oral lesions that interfered with his oral intake [ 110 ].…”
Extracorporeal photopheresis (ECP) is an apheresis procedure that is conventionally used as a first-line treatment for cutaneous and leukemic subtypes of T-cell lymphoma, such as Sezary’s syndrome and mycosis fungoides. Over the past three decades, its immunotherapeutic properties have been tested on a variety of autoimmune conditions, including many dermatologic diseases. There is ample evidence of ECP’s ability to modify leukocytes and alter cytokine production for certain dermatologic diseases that have been refractory to first-line treatments, such as atopic dermatitis. However, the evidence on the efficacy of ECP for the treatment of these dermatologic diseases is unclear and/or lacks sufficient evidence. The purpose of this paper is to review the literature on the utilization and clinical efficacy of ECP in the treatment of several [autoimmune] dermatologic diseases and discuss its applications, guidelines, recommendations, and future implementation for dermatologic diseases.
“…The majority of the ECP studies and case reports on pemphigus disease treatment pertains to PV ( n = 14) [ 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 ]. A recent retrospective study on the efficacy of ECP was conducted on eight patients who were diagnosed with drug-resistant PV and who were refractory to first-line treatments, such as corticosteroids and adjuvant therapies, such as colchine [ 104 ].…”
Section: Psoriasismentioning
confidence: 99%
“…Although the majority of the studies validate the hypothesis that ECP is beneficial for the treatment of bullous diseases, one recent case report states that high-intensity ECP failed to treat a patient with refractory PV after 5 months of treatment. Immunophenotyping showed no change in the auto-antibody desmoglein titers, and the patient continued to experience oral lesions that interfered with his oral intake [ 110 ].…”
Extracorporeal photopheresis (ECP) is an apheresis procedure that is conventionally used as a first-line treatment for cutaneous and leukemic subtypes of T-cell lymphoma, such as Sezary’s syndrome and mycosis fungoides. Over the past three decades, its immunotherapeutic properties have been tested on a variety of autoimmune conditions, including many dermatologic diseases. There is ample evidence of ECP’s ability to modify leukocytes and alter cytokine production for certain dermatologic diseases that have been refractory to first-line treatments, such as atopic dermatitis. However, the evidence on the efficacy of ECP for the treatment of these dermatologic diseases is unclear and/or lacks sufficient evidence. The purpose of this paper is to review the literature on the utilization and clinical efficacy of ECP in the treatment of several [autoimmune] dermatologic diseases and discuss its applications, guidelines, recommendations, and future implementation for dermatologic diseases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.